title: Role of angiotensin and endothelin in testicular ischemia reperfusion injury.
abstract: OBJECTIVE
  To determine whether angiotensin and endothelin have any role in testicular ischemia reperfusion injury by investigating the effects of the angiotensin converting enzyme inhibitor enalapril, selective non-peptide angiotensin-II type I blocker losartan and dual endothelin receptor blocker bosentan.
  
  
  METHODS
  Rats were anesthetized with thiopental sodium (50 mg/kg i.p.) before the operation. The left testicular artery and vein of rats were occluded for 1 h; before the bilateral orchiectomy, the organ was allowed to reperfuse for 3 h or 24 h. Enalapril (20 mg/kg i.p.), losartan (30 mg/kg i.p.), bosentan (10 mg/kg i.p.) or vehicle (saline) were given 30 min before reperfusion. Malondialdehyde level was measured in testicular tissue after 3 h of reperfusion. Histological examination was carried out after 24 h of reperfusion.
  
  
  RESULTS
  Ischemia reperfusion caused a significant increase in malondialdehyde level of ipsilateral testis, and histopathological injury in both ipsilateral and contralateral testes. Enalapril, losartan and bosentan treatments prevented the ischemia reperfusion-induced augmentation in malondialdehyde levels. Only bosentan treatment ameloriated ischemia reperfusion-induced histopathological alterations.
  
  
  CONCLUSIONS
  Endothelin might play a more important role in pathogenesis of testicular ischemia reperfusion injury when compared with angiotensin.
authors.affiliation: Department of Pharmacology, Institute of Health Sciences, Zonguldak Karaelmas University, Zonguldak, Turkey.
authors.forename: Burak
authors.initials: B
authors.lastname: Turkili
authors.forename: Zehra
authors.initials: Z
authors.lastname: Kurcer
authors.forename: Gunnur Ozbakis
authors.initials: GO
authors.lastname: Dengiz
authors.forename: Nilufer Onak
authors.initials: NO
authors.lastname: Kandemir
authors.forename: Gorkem
authors.initials: G
authors.lastname: Mungan
authors.forename: Veysel Haktan
authors.initials: VH
authors.lastname: Ozacmak
authors.forename: Zekiye Nur
authors.initials: ZN
authors.lastname: Banoglu
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000809:Angiotensins / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D000077300:Bosentan; D004656:Enalapril / Q000494:pharmacology; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000187:drug effects / Q000378:metabolism*; D019808:Losartan / Q000494:pharmacology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000378:metabolism* / Q000473:pathology; D018709:Statistics, Nonparametric; D013449:Sulfonamides / Q000494:pharmacology; D013737:Testis / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000809:Angiotensins; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D013449:Sulfonamides; D008315:Malondialdehyde; D004656:Enalapril; D019808:Losartan; D000077300:Bosentan